NYSE:AZN Astrazeneca Q3 2026 Earnings Report $156.91 -0.79 (-0.50%) Closing price 03:59 PM EasternExtended Trading$157.60 +0.69 (+0.44%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Astrazeneca EPS ResultsActual EPSN/AConsensus EPS $2.62Beat/MissN/AOne Year Ago EPSN/AAstrazeneca Revenue ResultsActual RevenueN/AExpected Revenue$16.07 billionBeat/MissN/AYoY Revenue GrowthN/AAstrazeneca Announcement DetailsQuarterQ3 2026Date10/30/2026TimeBefore Market OpensConference Call DateThursday, November 5, 2026Conference Call Time2:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Astrazeneca Earnings HeadlinesSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC DatrowayOctober 2 at 10:06 AM | finance.yahoo.comSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC DatrowayOctober 2 at 2:30 AM | businesswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 2 at 1:00 AM | Behind the Markets (Ad)Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor TypesOctober 2 at 2:30 AM | businesswire.comAstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street TargetsSeptember 30 at 11:17 AM | 247wallst.comIs AstraZeneca (LSE:AZN) Undervalued Following Its New Lung Cancer FDA Filing?September 30 at 10:17 AM | finance.yahoo.comSee More Astrazeneca Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astrazeneca? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astrazeneca and other key companies, straight to your email. Email Address About AstrazenecaAstrazeneca (NYSE:AZN) is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. Its research, development and commercial operations focus on prescription medicines for serious and chronic diseases, with an emphasis on discovering and delivering innovative therapies rather than operating as a diversified healthcare conglomerate. The company’s principal therapeutic areas include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunological conditions; and rare diseases. Its medicines include Tagrisso and Imfinzi for cancer, Lynparza for certain cancer indications, Farxiga for cardiovascular, kidney and metabolic conditions, Symbicort and Fasenra for respiratory diseases, and Ultomiris for selected rare disorders. AstraZeneca also develops medicines through internal research and partnerships with biotechnology and academic organizations. AstraZeneca was created in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group. The company serves patients and healthcare systems across numerous countries in North America, Europe, emerging markets and other international regions. Pascal Soriot has served as AstraZeneca’s chief executive officer since 2012.View Astrazeneca ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
